Johnson & Johnson (NYSE: JNJ) changed 1.73% to recent value of $133.46. The stock transacted 2,787,768 shares during most recent day however it has an average volume of 7.41M shares. It spotted trading – -10.42% off 52-week high price. On the other end, the stock has been noted 10.30% away from the low price over the last 52-weeks.
Johnson & Johnson (JNJ) recently reported it has committed to ensuring over $500M is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis (TB) by 2030. As one of the world’s largest healthcare companies, Johnson & Johnson is deeply engaged in global health innovation, working closely with governments and planned partners to improve the health and well-being of more people in more places about the world.
“No single institution can tackle the historic challenge of eliminating an infectious disease,” stated Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “By advancing our technologies, uniting our best scientists and leveraging decades of experience in HIV and TB, we’re optimistic that we can make a important contribution to the global effort.”
“Although HIV is now considered a chronic and manageable condition, people living with HIV still face a lifetime of taking daily pills. We therefore must continue to advance important innovations to help them,” stated Johan Van Hoof, MD, Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutical NV. “The global challenge remains immense. With 37M people about the world living with HIV – and nearly twoM people newly-infected each year – we cannot treat ourselves out of the HIV epidemic. Our ultimate goal must be to find a preventive vaccine for HIV.”
The company has 2.64B of outstanding shares and 346.91B shares were floated in the market. According to the most recent quarter its current ratio was 1.30 that represents company’s ability to meet its current financial obligations. JNJ has a gross margin of 66.80% and an operating margin of 23.40% while its profit margin remained 20.10% for the last 12 months. Its earnings per share (EPS) expected to touch remained 7.60% for this year while earning per share for the next 5-years is expected to reach at 6.04%.